製药、生物技术、医疗器材和诊断领域的资产购买交易（2016-2024）

本报告详细了解并分析了公司如何以及为何进行业务、产品、技术和特许权使用费等资产购买交易。

本报告提供了各方之间公布的资产购买交易的付款条件。这些资料提供了有关支付条款和其他交易条款的宝贵见解。

本报告重点在于可供购买的四种主要资产类型：

• 企业资产
• 产品资产
• 特许权使用费资产
• 技术资产
• 了解潜在合作伙伴谈判条款的弹性，并深入了解谈判过程，以了解条款谈判期间的预期结果。许多小型企业会要求提供付款条件的详细信息，但在包括付款方式和权利如何转让时，细节是关键。
• 本报告提供了自2016年以来宣布的资产购买交易的完整列表，目前协议案件/合作伙伴资料库中记录的内容，并包括可用的财务条款，以及公司及其合作伙伴向证券交易委员会提交的实际许可协议文件的线上副本的连结。

主要优点

本报告为读者提供了以下主要好处：

• 了解2016年以来的交易完成趋势
• 查看资产购买交易
• 基准分析：确定交易的市场价值
• 财务状况
• 交易清单：依公司名称（A-Z）、依治疗领域、依技术类型
• 主要交易（金额基础）
• 最活跃的交易者
• 每笔交易的资产识别和交易条件
• 取得合约文件：深入了解交易结构
• 实质审查：评估拟议交易条款对合作伙伴公司的适用性
• 节省数百小时的研究时间

调查范围

• 本报告目的是详细了解全球领先的生物製药公司的资产购买趋势和交易结构。

此报告包含以下资讯：

• 生命科学产业资产购买交易的趋势
• 资产购买交易结构：概览
• 药品、生物技术、医疗器材和诊断领域的资产购买交易记录列表
• 重大资产购买交易（价值基础）
• 最活跃的资产购买交易商
• 资产购买的主要合作伙伴资源

此报告按以下顺序列出了可用资讯的交易：

• 依公司名称（A-Z）
• 依交易金额
• 依治疗领域
• 依技术种类
• 每个交易标题都透过网路连结连结到实际交易记录的线上版本。
• 此报告提供对资产购买交易的可用合约文件的全面存取。

透过分析合约协议，实质审查可以：

• 授予和选择了哪些权利？
• 合约授予了哪些权利？
• 授予哪些专有权？
• 合约的付款结构是怎样的？
• 如何审核销售和付款？
• 合约期限是多久？
• 合约的主要条款是如何定义的？
• 如何对待和拥有知识产权？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和发布？
• 如何解决争议？
• 什么情况下可以取消合约？
• 如果所有者发生变化会怎样？
• 已商定何种类型的分授权或分包条款？
• 公司需要哪些样板条款？
• 哪些样板条款会根据合作伙伴和交易类型的不同而有所不同？
• 每家公司都主张合约法中的哪一个管辖权？

目录

执行摘要

第1章 简介

第2章 资产购买趋势

• 简介
• 资产购买的定义
• 资产购买趋势（2016年以来）
  • 资产购买交易：依年份（2016-2024年）
  • 资产购买交易：依发展阶段划分（2016-2024年）
  • 资产购买交易：依产业分类（2016-2024年）
  • 资产购买交易：依治疗领域分类（2016-2024年）
  • 资产购买交易：依技术类型划分（2016-2024年）
  • 资产购买交易：针对最活跃的公司（2016-2024年）
• 签订资产购买协议的原因
  • 企业资产
  • 产品资产
  • 特许权使用费资产
  • 技术资产
• 未来资产购买交易

第3章 资产购买交易结构概论

• 简介
• 资产购买结构

第4章 重大资产购买交易

• 简介
• 主要资产购买交易（金额基础）

第5章 最活跃资产购买者前25名

• 简介
• 前 25 名最活跃资产购买者（交易公司）

第6章 资产购买交易清单（含合约明细）

• 简介
• 资产购买交易协议（2016-2024年）
• 交易列表
• 交易清单：资产购买交易，依公司名称（A-Z）
• 交易清单：资产购买交易，依治疗领域
• 交易清单：资产购买交易，依技术类型
• 关于生物製药研究股份有限公司
• 目前的合作关係
• 当前合约
• Current Partnering 发布的最新报告标题

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

• Business assets
• Product assets
• Royalty assets
• Technology assets
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of asset purchase deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
• Chapter 3 provides an overview of the structure of asset purchase deals.
• Chapter 4 provides a review of the leading asset purchase deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
• Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
• The deal directory includes a comprehensive listing of all asset purchase deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
• The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2016.
• In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Key benefits

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse asset purchase deals
• Benchmark analysis - identify market value of transactions
• Financials - headline, upfront, milestone, royalty rates
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics includes:

• Trends in asset purchase dealmaking in the life sciences industry
• Overview of asset purchase deal structure
• Directory of asset purchase deal records covering pharmaceuticals, biotechnology, medical devices and diagnostics
• The leading asset purchase deals by value
• Most active asset purchase dealmakers
• The leading asset purchase partnering resources

In Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via hyperlink to an online version of the actual deal record, providing easy access to each contract document where available.
• Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals since 2016
  • 2.3.1. Asset purchase dealmaking by year, 2016-2024
  • 2.3.2. Asset purchase dealmaking by phase of development, 2016-2024
  • 2.3.3. Asset purchase dealmaking by industry sector, 2016-2024
  • 2.3.4. Asset purchase dealmaking by therapy area, 2016-2024
  • 2.3.5. Asset purchase dealmaking by technology type, 2016-2024
  • 2.3.6. Asset purchase dealmaking by most active company, 2016-2024
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts 2016-2024
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements, 2016-2024
• Figure 3: Asset purchase deals signed at each phase of development, 2016-2024
• Figure 4: Asset purchase deals by industry sector, 2016-2024
• Figure 5: Asset purchase deals by therapy area, 2016-2024
• Figure 6: Asset purchase deals by technology type, 2016-2024
• Figure 7: Top 25 most active asset purchase dealmakers, 2016-2024
• Figure 8: Top asset purchase deals by value, 2016-2024
• Figure 9: Most active asset purchase dealmakers, 2016-2024